Payment overview · 2025
General Payments
$215.00
11 reported records · 9 companies
Healthcare provider profile · identity verified
David J Brown, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SAINT LOUIS, MO · NPI 1861433195
Verified facts
What the public records show
CMS Open Payments records show David J Brown, M.D. received $215.00 in general payments during 2025 across 11 reported records.
ABBVIE INC. accounted for 30.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $64.89 | 30.2% | 3 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $32.87 | 15.3% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$21.56 | 10.0% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $16.96 | 7.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.70 | 7.8% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $15.89 | 7.4% | 1 | 2025 |
| Avanos Medical | Unresolved — no canonical attribution shown | $15.79 | 7.3% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.74 | 7.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.60 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $215.00 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $43.32 | 2 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $32.87 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $21.56 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| ON-Q PUMP AND ACCESSORIES Normalized: on q pump and accessories |
Device | Avanos Medical | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 61 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
95 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 924 | 259 |
| Amlodipine Besylate | Amlodipine Besylate | 664 | 208 |
| Levothyroxine Sodium | Levothyroxine Sodium | 626 | 177 |
| Lisinopril | Lisinopril | 526 | 150 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 393 | 120 |
| Losartan Potassium | Losartan Potassium | 378 | 117 |
| Metoprolol Succinate | Metoprolol Succinate | 325 | 91 |
| Simvastatin | Simvastatin | 309 | 86 |
| Alprazolam | Alprazolam | 276 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 273 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 263 | 79 |
| Omeprazole | Omeprazole | 241 | 75 |
| Metformin Hcl | Metformin Hcl | 231 | 74 |
| Tramadol Hcl | Tramadol Hcl | 226 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 206 | 65 |
| Gabapentin | Gabapentin | 198 | 69 |
| Zolpidem Tartrate | Zolpidem Tartrate | 189 | 41 |
| Trazodone Hcl | Trazodone Hcl | 183 | 54 |
| Allopurinol | Allopurinol | 179 | 54 |
| Eliquis | Apixaban | 166 | 39 |
| Lorazepam | Lorazepam | 165 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 159 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 154 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 144 | 43 |
| Famotidine | Famotidine | 142 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 142 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 52 |
| Meloxicam | Meloxicam | 138 | 47 |
| Finasteride | Finasteride | 131 | 35 |
| Sertraline Hcl | Sertraline Hcl | 130 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 127 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 117 | 37 |
| Furosemide | Furosemide | 112 | 48 |
| Carvedilol | Carvedilol | 111 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 108 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 108 | 29 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 104 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 101 | 26 |
| Synthroid | Levothyroxine Sodium | 95 | 24 |
| Bupropion Xl | Bupropion Hcl | 94 | 32 |
| Montelukast Sodium | Montelukast Sodium | 93 | 31 |
| Jardiance | Empagliflozin | 92 | 25 |
| Diazepam | Diazepam | 91 | 20 |
| Metformin Hcl Er | Metformin Hcl | 91 | 33 |
| Atenolol | Atenolol | 75 | 20 |
| Temazepam | Temazepam | 73 | 12 |
| Irbesartan | Irbesartan | 70 | 17 |
| Spironolactone | Spironolactone | 70 | 24 |
| Alendronate Sodium | Alendronate Sodium | 67 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 63 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 62 | 16 |
| Ozempic | Semaglutide | 61 | 11 |
| Potassium Chloride | Potassium Chloride | 61 | 22 |
| Valacyclovir | Valacyclovir Hcl | 59 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 58 | 14 |
| Telmisartan | Telmisartan | 58 | 16 |
| Donepezil Hcl | Donepezil Hcl | 55 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 17 |
| Azelastine Hcl | Azelastine Hcl | 52 | 17 |
| Clonazepam | Clonazepam | 51 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 15 |
| Glipizide | Glipizide | 50 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 14 |
| Ezetimibe | Ezetimibe | 45 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 16 |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 42 | 16 |
| Pregabalin | Pregabalin | 39 | suppressed |
| Fenofibrate | Fenofibrate | 38 | 11 |
| Lovastatin | Lovastatin | 38 | 13 |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Methocarbamol | Methocarbamol | 36 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 36 | suppressed |
| Klor-Con M20 | Potassium Chloride | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Testosterone | Testosterone | 34 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 15 |
| Dilt-Xr | Diltiazem Hcl | 33 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | 11 |
| Hydrocortisone | Hydrocortisone | 32 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 32 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Mirtazapine | Mirtazapine | 28 | 11 |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Nystatin | Nystatin | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | 13 |
| Glipizide Er | Glipizide | 26 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 25 | 25 |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | 15 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Gemtesa | Vibegron | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | 11 |
| Naproxen | Naproxen | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 18 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 17 | 17 |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Invokana | Canagliflozin | 17 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Indapamide | Indapamide | 14 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Folic Acid | Folic Acid | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Cimetidine | Cimetidine | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $215.00 · 11 records | ABBVIE INC. | FREESTYLE LIBRE 3, Heplisav-B, INCEPTIV, Leqembi, ON-Q PUMP AND ACCESSORIES, Ozempic, QULIPTA, Rybelsus, Tlando, UBRELVY, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error